OTCPK:HDII

Stock Analysis Report

Hypertension Diagnostics

Executive Summary

Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Risks

  • Hypertension Diagnostics has significant price volatility in the past 3 months.
  • Hypertension Diagnostics is not covered by any analysts.

Share Price & News

How has Hypertension Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

89.4%

HDII

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

29.5%

HDII

9.9%

US Medical Equipment

0.6%

US Market

HDII outperformed the Medical Equipment industry which returned 9.5% over the past year.

HDII outperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

HDIIIndustryMarket
7 Day89.4%1.1%-0.6%
30 Day494.1%0.6%2.2%
90 Day116.4%2.9%1.1%
1 Year29.5%29.5%10.8%9.9%2.9%0.6%
3 Year1920.0%1920.0%70.1%64.9%44.6%35.2%
5 Year203.0%203.0%138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Hypertension Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Hypertension Diagnostics undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Hypertension Diagnostics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Hypertension Diagnostics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Hypertension Diagnostics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hypertension Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of HDII’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Hypertension Diagnostics's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Hypertension Diagnostics performed over the past 5 years?

66.0%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Hypertension Diagnostics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Hypertension Diagnostics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Hypertension Diagnostics's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Hypertension Diagnostics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

Hypertension Diagnostics used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

It is difficult to establish if Hypertension Diagnostics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is Hypertension Diagnostics's financial position?


Financial Position Analysis

Hypertension Diagnostics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Hypertension Diagnostics's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Hypertension Diagnostics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Hypertension Diagnostics's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

Hypertension Diagnostics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Hypertension Diagnostics has less than a year of cash runway based on current free cash flow.

Hypertension Diagnostics has less than a year of cash runway if free cash flow continues to grow at historical rates of 0.8% each year.


Next Steps

Dividend

What is Hypertension Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Hypertension Diagnostics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Hypertension Diagnostics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Hypertension Diagnostics has not reported any payouts.

Unable to verify if Hypertension Diagnostics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Hypertension Diagnostics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Hypertension Diagnostics's salary, the management and board of directors tenure and is there insider trading?

23.7yrs

Average board tenure


CEO

Kenneth Brimmer (64yo)

8yrs

Tenure

US$287,697

Compensation

Mr. Kenneth W. Brimmer has been the Chief Executive Officer and President of HDI Plastics, Inc. since September 22, 2011. Mr. Brimmer has been Chief Executive Officer, Chief Financial Officer and President ...


Board Age and Tenure

23.7yrs

Average Tenure

74yo

Average Age

The average tenure for the Hypertension Diagnostics board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Kenneth Brimmer (64yo)

    CEO, President

    • Tenure: 8yrs
    • Compensation: US$287.70k
  • Joseph D’Albero

    Executive

    • Tenure: 0yrs
    • Compensation: US$178.84k
  • Maury Taylor

    Executive Director

    • Tenure: 0yrs

Board Members

  • Kenneth Brimmer (64yo)

    CEO, President

    • Tenure: 8yrs
    • Compensation: US$287.70k
  • Jay Cohn (88yo)

    Chairman of Scientific & Clinical Advisory Board

    • Tenure: 23.7yrs
  • Larry Leitner (66yo)

    Director

    • Tenure: 16.7yrs
  • Hans Brunner (82yo)

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0yrs
  • Daniel Duprez

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0yrs
  • Thomas Giles

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0yrs
  • Stevo Julius

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0yrs
  • Giuseppe Mancia

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0yrs
  • Karl-Heinz Rahn

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0yrs
  • Lawrence Resnick

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0yrs

Company Information

Hypertension Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hypertension Diagnostics, Inc.
  • Ticker: HDII
  • Exchange: OTCPK
  • Founded: 1988
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$4.145m
  • Shares outstanding: 136.81m
  • Website: https://www.hypertensiondiagnostics.com

Location

  • Hypertension Diagnostics, Inc.
  • 10501 Wayzata Boulevard
  • Suite 102
  • Minnetonka
  • Minnesota
  • 55305
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HDIIOTCPK (Pink Sheets LLC)YesCommon StockUSUSDAug 1998

Biography

Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and interna ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 23:36
End of Day Share Price2019/09/20 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.